Rationale Behind Baron Focused Growth Fund’s IDEXX Laboratories (IDXX) Holding
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Focused Growth Fund”. A copy of the letter can be downloaded here.
Idexx Laboratories Inc (IDXX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | BAMCO Inc. Ron Baron | 1,976,778 | $1,040,655,010 | +22% | 1.56% |
| 2. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 1,067,078 | $561,752,542 | +28% | 0.25% |
| 3. | Fundsmith LLP Terry Smith | 1,019,887 | $536,909,312 | -31% | 3.93% |
| 4. | Alyeska Investment Group Anand Parekh | 401,082 | $211,145,608 | +98% | 0.54% |
| 5. | Squarepoint Ops LLC Maxime Fortin (Cio) | 315,164 | $165,914,936 | +215% | 0.18% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $266.41 | 375 | $99,903.75 | 7,778 | 2019-08-06 | Filing | |
| $208.68 | 2,405 | $501,875.40 | 7,403 | 2019-02-05 | Filing | |
| $242.12 | 415 | $100,479.51 | 1,415 | 2018-08-03 | Filing | |
| $178.05 | 1,000 | $178,045.00 | 4,558 | 2018-02-14 | Filing | |
| $179.58 | 1,000 | $179,580.00 | 1,000 | 2018-02-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $634.57 | 1,758 | $1,115,577.22 | 18,141 | 2026-03-03 | Filing | |
| $663.04 | 2,589 | $1,716,620.66 | 83,606 | 2026-02-26 | Filing | |
| $662.16 | 1,000 | $662,156.70 | 86,195 | 2026-02-26 | Filing | |
| $661.10 | 1,200 | $793,317.12 | 87,195 | 2026-02-26 | Filing | |
| $659.75 | 2,859 | $1,886,223.82 | 88,395 | 2026-02-26 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,170,178 | $4,301,108,318 | 0.06% | |
| 2. | 5,152,213 | $2,712,331,011 | 0.06% | |
| 3. | 3,896,521 | $2,051,284,515 | 0.09% | |
| 4. | 3,748,660 | $1,973,444,570 | 0.06% | |
| 5. | 3,611,416 | $1,901,193,880 | 0.15% |
News See All
IDEXX Laboratories (IDXX) Looks Attractive on Recurring Revenue and High Customer Retention
Jensen Investment Management, an asset management company based in the US, released its second-quarter 2026 investor letter for the "Jensen Quality Growth Equity Strategy".
7 Best Pet Care Stocks to Buy for Consistent Recurring Revenue
The most durable cash flow in consumer markets may not come from subscriptions or software; it may come from the family dog.
11 Best Medical Technology Stocks to Buy Right Now
One of the key conclusions in EY’s 19th annual Pulse of the MedTech Industry Report is that the global medical technology market has moved from a period of post-pandemic turbulence into one of durable...
Do You Believe in the Long-Term Growth Potential of IDEXX Laboratories (IDXX)?
Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Asset Fund”. A copy of the letter is available to download here. U.S.
BofA Sees Slower InVue Installations as Headwind for IDEXX Laboratories, Inc. (IDXX)
TheFly reported on May 5 that IDXX saw its valuation outlook reduced as BofA Securities lowered its price target to $660 from $790 while maintaining a Neutral stance on the stock.
10 Best Cancer Stocks to Buy for the Long Term
Pharmaceutical firms have always had a special place in the healthcare market because they provide stability and expansion.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q1 2026 Earnings Call Transcript
Operator: Good morning, and welcome to the IDEXX Laboratories First Quarter 2026 Earnings Conference Call. As a reminder, today's conference is being recorded.
9 Best QQQ Stocks to Buy Now
On April 8, Yung-Yu Ma of PNC joined 'Fast Money' on CNBC to discuss the current market environment and noted that worst-case scenarios are not yet priced into the VIX or oil futures curves.
Reasons Why Hedge Funds Still Fancy IDEXX Laboratories, Inc. (IDXX)
On February 9, David Westenberg from Piper Sandler maintained his Overweight rating on IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Hedge Fund Resource Center